Evidence map›Paper›PMID 39834888›Full record

ArticleBioinorganic chemistry and applications2025

Decavanadate Compound Displays In Vitro and In Vivo Antitumor Effect on Melanoma Models.

Amine Essid, Ines Elbini, Regaya Ksiksi, Nardine Harrab, Wassim Moslah, Imen Jendoubi, Raoudha Doghri, Mohamed-Faouzi Zid, José Luis, Najet Srairi-Abid

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioinorganic chemistry and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amine EssidInstitut Pasteur de Tunis, LR20IPT01 Biomolécules, Venins et Application Théranostiques (LBVAT), University of Tunis El Manar, Tunis 1002, Tunisia.ORCID https://orcid.org/0009-0009-3956-6064
Ines ElbiniInstitut Pasteur de Tunis, LR20IPT01 Biomolécules, Venins et Application Théranostiques (LBVAT), University of Tunis El Manar, Tunis 1002, Tunisia.ORCID https://orcid.org/0000-0002-2224-0211
Regaya KsiksiFaculty of Sciences of Tunis, Laboratory of Materials, Crystal Chemistry and Applied Thermodynamics, University of Tunis El Manar, El Manar II, Tunis 2092, Tunisia.ORCID https://orcid.org/0000-0003-0454-8375
Nardine HarrabInstitut Pasteur de Tunis, LR20IPT01 Biomolécules, Venins et Application Théranostiques (LBVAT), University of Tunis El Manar, Tunis 1002, Tunisia.
Wassim MoslahInstitut Pasteur de Tunis, LR20IPT01 Biomolécules, Venins et Application Théranostiques (LBVAT), University of Tunis El Manar, Tunis 1002, Tunisia.ORCID https://orcid.org/0009-0003-9519-525X
Imen JendoubiFaculty of Sciences of Tunis, Laboratory of Materials, Crystal Chemistry and Applied Thermodynamics, University of Tunis El Manar, El Manar II, Tunis 2092, Tunisia.ORCID https://orcid.org/0000-0003-1056-1963
Raoudha DoghriLaboratoire de Médecine de Précision, Médecine Personnalisée et Investigation en Oncologie (LR21SP01), Service d'Anatomie Pathologique, Institut Salah Azaiez, Bab Saadoun, Tunis 1006, Tunisia.
Mohamed-Faouzi ZidFaculty of Sciences of Tunis, Laboratory of Materials, Crystal Chemistry and Applied Thermodynamics, University of Tunis El Manar, El Manar II, Tunis 2092, Tunisia.
José LuisInstitut de Neurophysiopathologie, INP, Faculté des Sciences Médicales et Paramédicales, CNRS, Aix-Marseille Université, Marseille 13005, France.ORCID https://orcid.org/0000-0001-7419-6016
Najet Srairi-AbidInstitut Pasteur de Tunis, LR20IPT01 Biomolécules, Venins et Application Théranostiques (LBVAT), University of Tunis El Manar, Tunis 1002, Tunisia.ORCID https://orcid.org/0000-0003-1296-0909

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of available treatments for melanoma is limited by side effects and the rapidly emerging resistance to treatment. In this context, the decavanadate compounds represent promising tools to design efficient therapeutic agents. In our study, we synthesized a dimagnesium disodium decavanadate icosahydrate compound (Mg

Indexed as

antitumor agentscancer inhibitorcell migrationdecavanadatemelanomapolyoxometalatespolyoxovanadate

Identifiers

PMID39834888
PMCPMC11742080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.